Document is current
Any future updates will be listed below
-
Authors
Ferrié, Martin
Alexandre, Virginie
Montpellier, Claire
Bouquet, Peggy
Tubiana, Thibault
Mézière, Léa
Ankavay, Maliki
Bentaleb, Cyrine
Dubuisson, Jean
Bressanelli, Stéphane
Aliouat-Denis, Cécile-Marie
Rouillé, Yves
Cocquerel, Laurence https://orcid.org/0000-0002-2136-5178
-
Funding
Funding for this research was provided by:
Institut Pasteur de Lille (Institut Pasteur de Lille, HEV-Cure)
Région Hauts-de-France (Région Hauts-de-France, HEV-Cure, Région Hauts-de-France)
Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ECTZ205629, ECTZ189696, AAP 2015-2, ECTZ74553, AAP 2015-2, ECTZ61515)
Inserm-Transfert (HEV-Cure)
Université de Lille (Université de Lille)
- License Information
-
More Information
Article History
Received: 13 October 2023
Revised: 3 July 2024
Accepted: 15 July 2024
First Online: 9 August 2024
Declarations
:
: This study does not include any human subjects.
: All authors read and approved the final manuscript.
: Claire Montpellier, Jean Dubuisson and Laurence Cocquerel are coinventors of two patent applications on the use of antibodies having specificity for the ORF2i protein for HEV diagnostic purposes. Patents have been filed by Inserm Transfert. The authors have no other financial or non-financial interests to disclose.
